Armata Pharmaceuticals posts Q2 net income of $74.1 million on non-cash gain
Armata Pharmaceuticals reported second-quarter 2026 net income of $74.1 million, driven by a $91.0 million non-cash gain from the change in fair value of its Convertible Loan. Operating loss widened to $10.3 million from $6.8 million a year earlier, and the company's cash and equivalents were $24.0 million at June 30, 2026, so the profit does not reflect improved operations.
Key points
- Q2 2026 grant and award revenue was $2.5 million, up from $2.2 million in Q2 2025.
- Q2 2026 research and development expenses rose to $7.6 million and general and administrative expenses to $5.2 million, mainly from higher non-cash stock-based compensation.
- Q2 2026 diluted loss per share was $0.27, compared with $0.45 in Q2 2025; basic earnings per share were $2.02.
- Six-month net loss widened to $41.2 million from $22.8 million; cash and equivalents were $24.0 million at June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.